Claudia Taborda Gómez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Claudia Taborda Gómez has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Agustín Jara
Instituto de Investigaciones Farmacológicas, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Ciudad Autónoma de Buenos Aires C1113AAA, Argentina
2 shared publications - Alberto Lazarowski
Instituto de Neurociencias de Castilla y León (INCYL), Universidad de Salamanca, 37007 Salamanca, Spain
2 shared publications - Florencia Fernandez
Instituto de Investigaciones Farmacológicas, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Ciudad Autónoma de Buenos Aires C1113AAA, Argentina
2 shared publications - Franco Moscovicz
Instituto de Investigaciones Farmacológicas, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Ciudad Autónoma de Buenos Aires C1113AAA, Argentina
2 shared publications - Jerónimo Auzmendi
Instituto de Investigaciones Farmacológicas, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Ciudad Autónoma de Buenos Aires C1113AAA, Argentina
2 shared publications - Luis Fernando Pacheco Otalora
Laboratorio de Investigación en Neurociencias, Instituto Científico, Universidad Andina del Cusco, Peru
2 shared publications
Latest Publications
- Open Access
- 11 August 2026
- Published by MDPI AG in Brain Sciences
- Vol. 16 (8) , 851
Subchronic Cannabidiol (CBD) Treatment During the Silent Period Fails to Prevent Increased Seizure Susceptibility Following Lithium-Pilocarpine-Induced Status Epilepticus
Introduction. In recent years, cannabidiol (CBD) has been used as an adjunct therapy to anti-seizure medications for the control of seizures in patients with drug-resistant epilepsy. In addition to its anticonvulsant effect, CBD also has well-defined anti-inflammatory properties. Since neuroinflammation can trigger various pro-epileptogenic mechanisms, CBD could play an inhibitory role in this process. Epileptogenesis is the process by which epilepsy becomes a chronic disease following a brain injury, and one of its main characteristics is an increased susceptibility to seizures due to a reduced seizure threshold. However, the role of CBD in modulating this susceptibility remains poorly understood. Methodology. We developed an experimental protocol to discretely measure the seizure threshold (DMST) 7 or 14 days after lithium-pilocarpine-induced status epilepticus (SE) through the administration of small intraperitoneal (i.p.) doses of pentylenetetrazol (15 mg/kg/every 10 min). Results. Using the DMST, we observed a significant decrease in the seizure threshold after SE associated with a hypersensitivity state characterized by irritability and marked weight loss. A separate cohort of rats was treated with CBD (20 mg/kg) for 14 days following SE. Conclusions. Treatment with CBD did not improve the seizure threshold; moreover, it worsened the hypersensitivity state and delayed recovery following SE. Our results suggest that orally administered CBD, at a human-equivalent therapeutic and safe dose, does not improve susceptibility to seizure development after SE.
- 11 August 2026
- Published by MDPI AG in Brain Sciences
- Vol. 16 (8) , 851
Open AccessSubchronic Cannabidiol (CBD) Treatment During the Silent Period Fails to Prevent Increased Seizure Susceptibility Following Lithium-Pilocarpine-Induced Status Epilepticus
Introduction. In recent years, cannabidiol (CBD) has been used as an adjunct therapy to anti-seizure medications for the control of seizures in patients with drug-resistant epilepsy. In addition to its anticonvulsant effect, CBD also has well-defined anti-inflammatory properties. Since neuroinflammation can trigger various pro-epileptogenic mechanisms, CBD could play an inhibitory role in this process. Epileptogenesis is the process by which epilepsy becomes a chronic disease following a brain injury, and one of its main characteristics is an increased susceptibility to seizures due to a reduced seizure threshold. However, the role of CBD in modulating this susceptibility remains poorly understood. Methodology. We developed an experimental protocol to discretely measure the seizure threshold (DMST) 7 or 14 days after lithium-pilocarpine-induced status epilepticus (SE) through the administration of small intraperitoneal (i.p.) doses of pentylenetetrazol (15 mg/kg/every 10 min). Results. Using the DMST, we observed a significant decrease in the seizure threshold after SE associated with a hypersensitivity state characterized by irritability and marked weight loss. A separate cohort of rats was treated with CBD (20 mg/kg) for 14 days following SE. Conclusions. Treatment with CBD did not improve the seizure threshold; moreover, it worsened the hypersensitivity state and delayed recovery following SE. Our results suggest that orally administered CBD, at a human-equivalent therapeutic and safe dose, does not improve susceptibility to seizure development after SE.
- Open Access
- 29 June 2026
- Published by MDPI AG in Preprints.org
Subchronic Cannabidiol (CBD) Treatment During the Silent Period Fails to Prevent the Increased Seizure Susceptibility Following Lithium Pilocarpine-Induced Status Epilepticus
In recent years, cannabidiol (CBD) has been used as an adjunct therapy to anti-seizure medications for the control of seizures in patients with drug-resistant epilepsies. In addition to its anticonvulsant effect, CBD also well-defined anti-inflammatory properties. Since neuroinflammation can trigger various pro-epileptogenic mechanisms For this reason, CBD could play an inhibitory role in this process. Epileptogenesis is the process by which epilepsy becomes a chronic disease following a brain injury and one of its main characteristics is an increased susceptibility to seizures due to reduced seizure threshold. However, the role of CBD in modulating this susceptibility remains poorly understood. We developed an experimental protocol to discretely measure seizure threshold (DMST) 7 or 14 days after lithium-pilocarpine-induced status epilepticus (SE) through the administration of small intraperitoneal (i.p.) doses of pentylenetetrazol (15 mg/kg/ every 10 minutes). Using the DMST, we observed a significant decrease in seizure threshold after SE associated with a hypersensitivity state characterized by irritability and marked weight loss. A separate cohort of rats was treated with CBD (20mg/kg) for 14 days following SE. Treatment with CBD did not improve seizure threshold, moreover, it worsened the hypersensitivity state, and delayed the recovery following SE. Our results suggest that orally administered CBD, at a human therapeutically recommended and safe dose, does not improve susceptibility to seizure development after SE.
- 29 June 2026
- Published by MDPI AG in Preprints.org
Open AccessSubchronic Cannabidiol (CBD) Treatment During the Silent Period Fails to Prevent the Increased Seizure Susceptibility Following Lithium Pilocarpine-Induced Status Epilepticus
In recent years, cannabidiol (CBD) has been used as an adjunct therapy to anti-seizure medications for the control of seizures in patients with drug-resistant epilepsies. In addition to its anticonvulsant effect, CBD also well-defined anti-inflammatory properties. Since neuroinflammation can trigger various pro-epileptogenic mechanisms For this reason, CBD could play an inhibitory role in this process. Epileptogenesis is the process by which epilepsy becomes a chronic disease following a brain injury and one of its main characteristics is an increased susceptibility to seizures due to reduced seizure threshold. However, the role of CBD in modulating this susceptibility remains poorly understood. We developed an experimental protocol to discretely measure seizure threshold (DMST) 7 or 14 days after lithium-pilocarpine-induced status epilepticus (SE) through the administration of small intraperitoneal (i.p.) doses of pentylenetetrazol (15 mg/kg/ every 10 minutes). Using the DMST, we observed a significant decrease in seizure threshold after SE associated with a hypersensitivity state characterized by irritability and marked weight loss. A separate cohort of rats was treated with CBD (20mg/kg) for 14 days following SE. Treatment with CBD did not improve seizure threshold, moreover, it worsened the hypersensitivity state, and delayed the recovery following SE. Our results suggest that orally administered CBD, at a human therapeutically recommended and safe dose, does not improve susceptibility to seizure development after SE.